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UNDERSTANDING NANOG’S ROLE IN CANCER BIOLOGY
Mark Daniel Badeaux, B.S.
Supervisory Professor Dean Tang, PhD
The cancer stem cell model holds that tumor heterogeneity and population-level
immortality are driven by a subset of cells within the tumor, termed cancer stem cells.
Like embryonic or somatic stem cells, cancer stem cells are believed to possess selfrenewal capacity and the ability to give rise to a multitude of varieties of daughter cell.
Because of cancer’s implied connections to authentic stem cells, we screened a variety
of prostate cancer cell lines and primary tumors in order to determine if any notable
‘stemness’ genes were expressed in malignant growths. We found a promising lead in
Nanog, a central figure in maintaining embryonic stem cell pluripotency, and through a
variety of experiments in which we diminished Nanog expression, found that it may play
a significant role in prostate cancer development. We then created a transgenic mouse
model in which we targeted Nanog expression to keratin 14-expressing in order to assess
its potential contribution to tumorigenesis. We found a variety of developmental
abnormalities and altered differentiation patterns in our model , but much to our chagrin
we observed neither spontaneous tumor formation nor premalignant changes in these
mice, but instead surprisingly found that high levels of Nanog expression inhibited
tumor formation in a two-stage skin carcinogenesis model. We also noted a depletion of
skin stem cell populations, which underlies the wound-healing defect our mice harbor as
well. Gene expression analysis shows a reduction in c-Jun and Bmp5, two genes whose
loss inhibits skin tumor development and reduces stem cell counts respectively.
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As we further explored Nanog’s activity in prostate cancer, it became apparent
that the protein oftentimes was not expressed. Emboldened by the competing
endogenous RNA (ceRNA) hypothesis, we identified the Nanog 3’UTR as a regulator of
the tumor suppressive microRNA 128a (miR-128a), which includes known oncogenes
such as Bmi1 among its authentic targets. Future work will necessarily involve
discerning instances in which Nanog mRNA is the biologically relevant molecule, as
well as identifying additional mRNA species which may serve solely as a molecular sink
for miR-128a.
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I. K14. Nanog Transgenic Mouse Model
Chapter 1- Introduction and Background
Introduction
Tumors are immortal, heterogeneous tapestries woven of various malignant cells,
yet these disparate threads do not all have the same malignant potential. The cancer
stem cell model posits a hierarchy existing in tumor cells that is similar to hierarchies
that may be found in many adult somatic tissues. In an effort to understand at the
molecular level some of the resemblance between cancer cells and stem cells, we have
identified a number of stem cell genes that are expressed in prostate cancer and have
focused on a particularly interesting master regulator of embryonic stem cells known as
Nanog. Extensive loss-of-function studies demonstrated that Nanog depletion greatly
inhibited tumor development in xenograft models of prostate cancer. In order to model a
potential role for Nanog in tumorigenesis, we created transgenic mice in which tumorderived Nanog cDNA is driven by the keratin 14 promoter, thereby targeting its
expression to a variety of stem cell populations.

Background
Adult stem cells and the cancer stem cell model
For many years it has been appreciated that tumors are possessed of multifarious
cell types; what is less clear is the origin of these disparate sorts of cell. Long-standing
dogma has it that genetic instability in tumor cells produces competing cells within a
tumor; cells that bear mutations that confer a selective advantage become dominant (1).
This clonal evolution model is thought to operate dynamically and constantly in cancer,
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such that sharp changes in the tumor’s environment (such as those that occur when
chemotherapy is begun) are met with an ever-adapting population. In sharp contrast to
this model is the cancer stem cell (CSC) hypothesis, which postulates that cells bearing
many of the same properties as adult stem cells generate the myriad cell types present in
a given tumor (2); these properties may include self-renewal, relative dormancy, and an
increased tolerance for genomic damage (as often occurs in chemotherapeutic regimens).
In normally-functioning adult organs, tissues are highly organized and, for the
most part, are arranged in a discernibly hierarchical manner with stem cells occupying
the apex. Oftentimes, the immediate progeny of adult stem cells is the transit-amplifying
(TA) cell, also known as the progenitor cell. These cells are characterized by high
immediate proliferative activity, and the progenitor sits upstream of mature, terminallydifferentiated cells. This latter cell type is the functional effector of its respective organ,
and is characterized by a highly-specialized transcriptional program. These cells have
also irrevocably committed to their fate, and are generally believed to lose the ability to
proliferate. The notion that similar hierarchies exist in cancers is not a new one, but with
the emergence and refinement of several techniques, especially fluorescence-activated
cell sorting (FACS), amenable to isolating cell populations of interest, this notion has
been much easier to test. The CSC model gained significant traction in the mid-1990’s
after two seminal studies by the Dick lab involving acute myelogenous leukemia (AML)
in which they demonstrated that CD34+, CD38- cells alone could generate
transplantable leukemia (3, 4). CD34+/CD38- is, not coincidentally, the cell-surface
phenotype borne by human hematopoietic stem cells.
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There has been much confusion in the scientific community due to the moniker
“cancer stem cell”. The term is functional and refers to the cell population that can
regenerate tumors in a xenograft setting; to demonstrate self-renewal (of the tumor) with
a reasonable degree of certainty, xenografts are done iteratively for several generations
of tumor. Additionally, these tumors must recapitulate the heterogeneity seen in the
parental tumor to fully fit the definition of cancer stem cell. This heterogeneity is thus
assumed to arise from the ability of the CSC to give rise to its own spectrum of
cancerous progeny. CSCs need not necessarily originate from normal stem cells,
although it is quite likely that, owing to the long-lived nature of adult stem cell
populations, these more primitive cells are indeed prime targets for transformation.
Progenitor cells, having replicative ability and some limited self-renewal abilities, may
also suffer genetic and epigenetic alterations that yield CSCs. It is unknown if
terminally differentiated cells can undergo dedifferentiation or can be transformed into
cancer stem cells, although such a scenario is considered unlikely.
Also unknown is whether solid tumors are arranged hierarchically, as many
blood cancers seem to be. One of the earliest reports identified cancer stem cells in
breast cancers (5), although the fact that the samples utilized were not primary tumors,
but rather pleural effusions and metastases, left open the question of whether or not
primary breast tumors in fact were arranged in a hierarchy. In the past ~7-8 years, there
has been a deluge of reports claiming identification of CSC populations in nearly every
sort of solid tumor. Upon closer inspection, however, many of these reports are
incomplete, oftentimes lacking the gold standard of serial in vivo xenotransplantation
assays and/or demonstration of phenotypic heterogeneity in tumor regrowths.
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The question of whether prostate cancers behave according to the cancer stem
cell model is the subject of many labs’ research, including our own. This question has
been impossible to definitively address, as technical limitations render xenograft
regrowth of primary prostate tumors null. This is even true when employing different
sites of injection and/or adding Matrigel or other reagents to augment cell engraftment.
Instead, xenograft prostate tumors or tumors derived from pre-established cancer cell
lines, e.g., PC3, DU145, and LNCaP have been used as surrogates in these experiments.
In this context, it has been shown that CD44+ cells are significantly enriched in CSC
activity (6).

Embryonic stem cells and cancer
Superficially, one may see a resemblance between an embryo and a cancerous
growth, in that both have a high rate of proliferation, near-limitless proliferative
potential, and exist in an undifferentiated state. However, the embryo is carrying out a
highly orchestrated program that results in a functional organism, whereas the neoplasia
grows wantonly. There remains nonetheless a connection between the two, for the
embryo and its in vitro derivative, the embryonic stem cell (ES cell), possess two traits
important for sustained activity: They are multipotent, that is, they can give rise to
numerous cellular lineages, and they possess the quality of self-renewal, or the ability to
replenish themselves at the population level. Both of these qualities are evident in
cancers as well, leading one to wonder if perhaps they share any common molecular
features as well. In the past four years, a number of groups have conducted large-scale
gene expression forays in which similarities between ES cells and various cancers,
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including lung and bladder malignancies, have been noted (7-9). An underlying
assumption of such similarities is a global similarity in epigenetic landscape that is then
manifested in the form of gene expression mimicry.

It has been reported that

intractable hypermethylation of the promoter regions of Polycomb group target genes
occurs both in ES cells and in many cancer cells as well (10); enticingly, many of these
genes are established or candidate tumor suppressors. Additionally, it has been
speculated that the presence of a bivalent chromatin state in ES and adult stem cells, one
composed of methylation at the tail of histone 3 at lysine 27 and at lysine 4, and one that
is believed to be poised for activation of neighboring genes, may predispose cancer cells
to repression of these genes through a scant few additional repressive events (11).
Reports of shared gene expression such as those enumerated above raised the
question as to whether or not ES cells share common transcriptional machinery with
somatic cancer cells. Nanog, Oct4, and Sox 2 represent the core triad of transcription
factors that serve to maintain the pluripotent (able to give rise to all cell lineages save
placental) state, acting as hubs in a large-scale protein network dedicated to pluripotency
(12, 13). Quite often, these transcription factors work together, occupying each other’s
promoters and binding many common promoter regions as well (14). In fact, binding of
multiple (more than four) transcription factors is oftentimes required for gene expression
from a particular locus in ES cells, and those genes with low transcription factor
occupancy tend to be inactive (13).
Numerous studies have claimed re-expression of ES cell transcription factors in
human cancers, although closer inspection reveals that the most substantive data is found
at the level of mRNA expression, while confirmed reports of the ES cell transcription
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factors themselves, such as Nanog’s role in glioma stem cells (15), are scarce. There
have been, however, a number of systems generated in order to test the potential
contribution of these molecules to cancer development, e.g., Oct-4 and Nanog, when
expressed together in a lung adenocarcinoma cell line (A549), result in increased in vitro
sphere formation, an increase in the putative CSC population marked by CD133+, and
larger tumors in a subcutaneous xenograft assay of tumor development (16). The most
compelling of these systems has been in the form of transgenic mouse models; because
transcription factors are likely to exert highly cell-type-specific effects (see Klf4, whose
overexpression in the breast is tumor inhibitory but leads to dysplasia in epidermal basal
keratinocytes (17-19)), systems that target multiple organs are likely to yield the most
comprehensive and useful insights.

A provocative study performed by the Jaenisch lab,

which employed a doxycycline-inducible mouse model of Oct-4 overexpression from
the Collagen1a1 locus, demonstrated epithelial dysplasia and epidermal tumor growth
upon activation of Oct-4 (20). The authors concluded, however, that despite its powerful
potential contribution to tumor development, it was surprising that the molecule was
rarely re-expressed in human tumors. This fact suggested to them that the molecule was
under epigenetic “lock and key,” perhaps because of its oncogenic potential.

Nanog in ES cells
As mentioned previously, Nanog is a homeobox transcription factor essential to
maintaining pluripotency; it consists of 305 amino acids in both human and mouse
homologues, and as such has a predicted molecular mass of 34 kilodaltons (Figure 1-1).
The human and mouse Nanog proteins are ~60% similar at the amino acid level, but the
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critical DNA-binding domains of the two proteins share over 90% homology. The
protein is organized into five functional domains: The N-terminal domain seems to
represent a docking site for other proteins (21), while the homeodomain is responsible
for DNA-binding. The C-terminal domains have transactivating ability (22-24), and
between them lies the unique tryptophan repeat domain in which every fifth amino acid
residue is a tryptophan. This WR region is essential for Nanog dimerization, without
which it cannot function to propagate the pluripotent state (25). In ES cells, Nanog
exists in a variety of protein complexes that range in size from 160kD to over 1
megadalton (12). Its gene was cloned as part of a cDNA library screen to identify
factors responsible for scant yet reproducible mouse ES cell propagation in the absence
of leukemia-inhibitory factor (LIF) (26, 27), which is necessary for mouse ES cell
growth but dispensable for proliferation of human ES cells. ES cells that have been
engineered to lack Nanog can surprisingly self-renew, but in chimeric mice these cells
cannot form functional germ cells. Due to its role in establishing the inner cell mass
(ICM) of embryos as well as in creating mature germ cells, it has been postulated that
Nanog serves to resist differentiation signals, holding open a figurative window of
pluripotency (28).
The vast body of scientific study that has arisen in the wake of Yamanaka and
colleagues’ discovery that adult somatic cells can be reprogrammed into ES-like cells
called induced pluripotent cells (iPS cells) (29) has also led to insights concerning the
factors that are crucial for this process. Unsurprisingly, Nanog is a central figure in this
reprogramming: Without Nanog, partially de-differentiated/reprogrammed
intermediates cannot attain full pluripotency. ES cells that lack Nanog cannot invoke
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reprogramming of somatic cells in the context of cell fusion, and Nanog has also been
found to mark the developing epiblast. In fact, in the absence of Nanog, the ICM forms
but cannot attain full pluripotency; for this and the reasons enumerated above, it has
been suggested that Nanog acts as the conduit to “ground state pluripotency” (30).

Nanog in cancer
Nanog expression has been reported in a variety of cancer types at the protein
level, e.g., (31-33), although the veracity of many of these reports is questionable due to
several concerns including reagent specificity. More compelling evidence of Nanog
gene expression exists in the form of mRNA-related data, e.g., (34-37). Our lab
conducted pilot studies in a variety of prostate cancer cell lines, xenografts, and primary
tumors in order to determine which potential stem cell factors were expressed in this
spectrum of diseases, and found consistent expression of a Nanog retrogene, NanogP8,
which encodes a protein identical to that encoded by the canonical Nanog gene (38).
We then asked whether expression of Nanog may be important in tumor development.
To answer this question, we conducted loss-of-function studies, utilizing Nanog small
interfering RNA (siRNA) to show that diminishing Nanog levels reduces in vitro serial
sphere-propagating ability, and utilizing lentiviral-mediated short hairpin RNA (shRNA)
to show decreased tumorigenesis in subcutaneous xenografts of various cancer cell lines.
For technical reasons, including unexplained cell death when overexpressing Nanog
cDNA, we decided to conduct gain-of-function studies in a transgenic mouse model.
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Figure 1-1

Figure 1-1 The Nanog protein
Nanog is a transcription factor comprised of 305 amino acids which has five known
functional domains, as depicted in (A). It is one of the central hubs in the proteinprotein interaction network devoted to maintaining pluripotency in the ICM(B), and
associates cooperatively with other hub molecules such as Oct4, or repressively as
exemplified by its binding to Smad1 which blocks Bmp signaling.
Figure 1-1B is adapted from Wang et al. 2006 Nature 444:364-368.
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We chose to utilize the keratin 5/keratin 14 promoters as they target basal cell
populations in stratified squamous epithelia (39-42); these basal cells are known to
harbor stem and/or progenitor cell populations. These promoters have been shown to
cause the most dramatic phenotypes in the skin, as promoter expression is strongest in
this tissue. Additionally, we chose to target the prostate, as most of our Nanog studies
centered on prostate cancer, and therefore utilized the ARR2Pb promoter which has
activity primarily in luminal cells of the prostate (43, 44).

Mouse skin and skin stem cells
The skin is a protective organ whose primary role is to serve as a barrier between
an organism and its environment, and it is composed of three important regions: The
epidermis is home to epithelial cells that are nucleated, express keratins 5 and 14 (K5
and K14), and are situated near the basement membrane but enucleate as they detach,
begin to express keratins 1 and 10 (K1 and K10), and move suprabasally to form the
highly keratinized, waxy outer layer of skin. The dermis is populated chiefly by
fibroblasts and is the region in which hair follicles and sebaceous glands are anchored.
The hypodermis is primarily composed of fat and is an important mediator of
temperature regulation, one of the skin’s ancillary duties. Contributing to this
phenomenon in humans are sweat glands that secrete fluid when body temperature rises;
evaporation of sweat removes heat from the body. In colder climes, body hair serves to
retain heat. Mice lack the ability to sweat but retain body heat in part through the
copious amount of fur that covers most of the animal, save the tail and feet.
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Anatomically, this distinction means that hair follicular density in mouse skin is much
greater than that in human skin.
The differences in anatomical structure between adult human and mouse skin
extend to the location of their respective stem cell populations. In human skin, the basal
layer of the epidermis has been shown to harbor cells capable of extensive clonal growth
ex vivo. Because of the relative paucity of hair follicles in the human skin, it is thought
that the basal epidermal keratinocytes are the primary stem cell pool. It should be noted
that many of the techniques available to study mouse skin, such as lineage tracing and
label-retention, are quite obviously not available to employ in human systems for ethical
reasons, and therefore knowledge of human skin stem cells is scant when compared with
the findings in mouse skin.
The murine interfollicular epidermis (IFE) is home to a population of basal cells
with capacity for clonal expansion in vivo during steady-state conditions, and is thought
to be the hub of the so-called epidermal proliferative unit (EPU) coined by Chris Potten
(45). There is some controversy as to whether these cells represent true stem cells or socalled progenitor/transit-amplifying cells, but this may be a semantic argument, as
functionally these “stem” cells are responsible for clonal repopulation of a localized area
of the IFE.
Adult mouse skin’s resident stem cells are primarily localized in the hair follicle,
and consist of several distinct populations, although it should be noted with some
caution that the degree of overlap as well as the lineage relationships among these
populations has not been fully explored, and given the rash of new stem cell populations
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discovered in this tissue in the past two years, it is likely that there are as-yetundiscovered mouse skin stem cells.
The classical method for identifying mouse skin stem cells is the label-retaining
experiment, first conducted using tritium-laden thymidine that is incorporated into DNA
during S phase of the cell cycle (46), and now commonly performed using 5’-bromo 2’deoxyuridine (BrdU) in its stead. Label-retaining cells (LRCs) are identified by first
pulsing the mouse with the label to be used; the pulse is performed for a sufficient length
of time such that all cells under study have been allowed to proliferate, and therefore
have taken up the label. The subsequent “chase” period is the empirically-determined
window of time that the label is diluted through multiple rounds of cell division; only
cells that have remained relatively quiescent during the chase will still bear the initial
label at a detectable level. This method for detecting quiescent skin cell populations
revealed the presence of LRCs in the bulge region of the hair follicle as well as in the
basal layer of the IFE.
Ex vivo, keratinocytes (usually from newborn mice, although adult keratinocytes
can be used as well, albeit at much lower efficiencies) can be plated at clonal density on
a low (~one-third confluent) density of 3T3 mouse fibroblast cells or on a variety of
substrates (e.g. laminin, collagen IV) in defined media supplemented with growth factors
and allowed to form colonies. Tightly packed growths, known as holoclones, are
believed to contain stem cells, whereas less-organized meroclones and paraclones may
contain progenitors and differentiated cells, respectively (47).
The preferred current method of distinction among various cell populations is by
way of cell-surface marker profile, since these populations can be prospectively isolated
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by FACS and assayed for stem cell function by engrafting the population of interest,
along with newborn dermal fibroblasts, onto the backs of immunocompromised mice
and assessing the degree of contribution to new IFE, hair follicles, and sebaceous glands.
The chief resident hair follicle stem cell population is thought to be the alpha-6
integrin+, CD34+ cells in the bulge region. A subset of these cells additionally are
LRCs, and this population is capable of reconstituting the epidermal lineages, including
the IFE, the hair follicle, and the sebaceous gland, in their entirety. Current thought
therefore places these cells at the top of the hair follicle stem cell hierarchy, as they
demonstrate multipotency in vivo and in ex vivo artificial systems.
Bulge cells co-expressing CD34 and leucine-rich repeat-containing G-proteincoupled receptor 5 (Lgr5) surprised researchers as they were found to be able to
reconstitute all epidermal lineages in transplantation experiments but were also found to
be actively cycling (48). This finding challenged the paradigm of stem cells in the skin
existing solely in a relatively quiescent state.
The observation that upon wounding, stem cells are surprisingly recruited from
the infundibulum and isthmus rather than from the bulge and contribute significantly to
the repair of affected areas, suggests that bulge keratinocytes are not the only reservoir
of follicular stem cells. Leucine-rich immunoglobulin-like 1 (Lrig1)-positive cells lie in
the junctional zone between the infundibulum and the IFE. As Lrig1 is a
transmembrane, cell surface protein whose known role is to restrict epidermal growth
factor receptor (EGFR) signaling by targeting it for ubiquitination and therefore
degradation following EGFR stimulation (49, 50), it is thought to promote a relatively
quiescent state. Although Lrig1+ cells are capable, when mixed with neonatal dermal
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fibroblasts and grafted onto immunocompromised hosts, of reconstituting all epidermal
cell types, lineage tracing experiments suggest that this population replenishes only the
IFE and the sebaceous glands during normal homeostasis (51).
Leucine-rich repeat-containing G-protein-coupled receptor 6 (Lgr6)-positive
cells represent an interesting population, as they generate the three epidermal
components prenatally, yet the adult population directly above the bulge only gives rise
to IFE and sebaceous gland, but was found to be involved in wound repair (52). There is
some overlap between the Lrig1+ and Lgr6+ populations, but the extent of this shared
pool has not been analyzed.
MTS 24-positive cells consist of two sorts: Some lie directly above those cells
that express CD34, and it has been noted that this population contains LRCs, although its
ability to reconstitute hair follicles in a transplantation assay is unknown (53). Another
population cycles actively and has been shown to generate the three broad epidermal cell
types .

Two-stage skin carcinogenesis
A two-stage chemically-induced carcinogenesis protocol is among several
experimental models available to researchers with an interest in studying tumor
development in the skin. It lists among its strengths the ability to delineate between the
initiation and promotion phases of tumor development, and is easily superimposed upon
pre-existing transgenic or knockout mouse lines as both the initiator and promoter may
be delivered topically.
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Figure 1-2

Figure 1-2 Known stem cell populations in the murine hair follicle
A number of cell-surface markers define stem cell populations in the hair follicle. The
degree of overlap and lineage relationship among the various populations is currently the
subject of much research. For further descriptions of each stem cell population please
see the body of the text.
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Genetic lesions are introduced into skin stem and progenitor cells (54) found in both the
interfollicular epidermis and the hair follicle (55) by application of a single subcarcinogenic dose one of a diverse array of initiating compounds, among which 7,12dimethylbenz[a]anthracene (DMBA) is the most widely used. Two members of the Ras
G protein-coupled receptor family, Hras and Kras, sustain the relevant DMBA-induced
mutational burden, resulting in largely dormant mutation-bearing cell populations that
await proliferative stimuli in order to clonally expand. It should be noted that the
genetic insults induced by many initiators, including DMBA, are largely irreversible;
accordingly, intervals between initiator and promoter treatment may span a range from
two weeks to many months.
After the initiator has been allowed sufficient time to be metabolized, the tumor
promotion phase may begin. Typically, 12-O-Tetradecanoylphorbol-13-acetate (TPA)
or another phorbol ester compound is used to induce cellular proliferation. TPA does so
by activating Protein Kinase C (PKC), as TPA resembles diacylglycerol, one of PKC’s
endogenous triggers. PKC phosphorylates many proteins at serine and threonine
residues; among the most important in the context of its activation in the two-stage
carcinogenesis protocol is epidermal growth factor receptor (EFGR). Indeed, signaling
through PKC and in turn through EGFR has been shown to also activate Akt (protein
kinase B) as a further downstream consequence (56). Essentially, a host of
phosphorylation events are initiated and signaling pathways activated when TPA is
applied to the skin. The tumor promoter is generally applied topically two or more times
per week, and it is essential that a regular schedule is adhered to, as the effects of
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promoters are reversible, i.e., hyperplasia or papillomas induced by promotion will
recede in the absence of treatment. Promotion may last for 20 weeks to a full year, and
during this time course epidermal hyperplasia will yield benign exophytic papillomas;
cells in these small tumors may eventually sustain sufficient additional genetic insults
such that the papilloma will progress to a squamous cell carcinoma (SCC). SCCs
resulting from the two-stage skin carcinogenesis protocol are in many respects similar to
those that occur spontaneously in humans, and may be identified by their endophytic,
vascularized nature.
There are several practical advantages to using a two-stage protocol rather than a
one-stage, or complete, method. In the latter, the distinction between initiation and
promotion is obfuscated, while in the former both are readily separable (57). In such a
setting, a gene or compound of interest may be more accurately described with respect to
its role in skin carcinogenesis. Additionally, a gene’s contribution to the progression
from premalignant lesion to frank cancer may also be assessed. In any skin
carcinogenesis protocol, mouse models that are recalcitrant to spontaneous tumor
development may still be studied in the context of carcinogenesis.
It is also important to note the limitations of this experimental model. First, it
does not accurately recapitulate the genetic underpinnings of human skin cancer, as
SCCs in this model are Ras-driven, while human skin cancers are largely reliant on p53
inactivation (58). Additionally, it cannot be used to address other cancer types due to the
need for topical application of the relevant chemicals. Finally, metastasis of the SCCs
produced is rare, relegating the protocol chiefly to the study of benign growths and
primary tumors.
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Anatomy of the prostate
The prostate is a small, hormone-responsive, exocrine organ tasked with
producing and secreting fluids that aid in sexual reproduction. The mouse prostate is
grossly unlike that of humans, in that the latter is a small uniform walnut-sized organ
while the latter contains four lobes (anterior, dorsal, lateral, and ventral) arranged around
the urethra. Histologically, however, the two are organized similarly: The tubules that
comprise the gland possess epithelial cells that overlie supporting stroma. The prostatic
epithelium consists of basal cells that are anchored to the basement membrane and that
express K5 and K14, differentiated secretory luminal cells that express keratins 8 and 18
(K8 and K18), and neuroendocrine cells that are interspersed throughout the basal layer.
The most commonly used construct for targeting a gene of interest to the prostate
is the androgen-responsive probasin promoter, or more properly, the artificial derivative
known as the ARR2Pb promoter, which has two androgen response regions (ARRs)
immediately upstream of the minimal probasin promoter (44). Genes cloned into
constructs bearing this promoter are expressed primarily in the luminal cells of the
mouse prostate, although scant expression in basal and even stromal compartments can
be observed (unpublished observations). Expression is likewise stronger in some lobes
than others, with dorsal and ventral expression being much higher than expression in the
anterior prostate ((44) and unpublished observations). The promoter is extremely
sensitive to androgen levels, and as such achieves maximum activity as the mouse
reaches sexual maturity at roughly eight weeks of age (44).
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Proliferative diseases of the prostate
Two of the most common diseases of the prostate are benign prostatic
hyperplasia and prostate cancer. The latter is of particular importance since it may
metastasize and cause significant mortality in untreated or treatment-refractory male
populations. Prostate cancer in humans occurs in a multi-step fashion, from normal
gland to prostatic intraepithelial neoplasia (PIN) lesion to prostatic adenocarcinoma.
The cell of origin for prostate cancer is a point of contention among various groups, but
decades of pathological evidence suggests that luminal expansion is the primary
manifestation of the disease.
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Chapter 2- Materials and Methods
Mouse Housing and Care
All housing and procedures were carried out in an animal facility accredited by
the American Association for the Assessment and Accreditation of Laboratory Animal
Care, in accordance with Institutional Animal Care and Use Committee guidelines.
Mice were fed ad libitum unless otherwise noted.

Generation of K14-NanogP8 Mice
The basic procedures for establishing transgenic (Tg) animals have been
previously described. Briefly, the NanogP8 open-reading frame cDNA derived from
HPCa5T, a primary human prostate tumor, was cloned into the multiple cloning site
(MCS) of the pBluescript-human keratin 14 vector, in which the human keratin 14
promoter is immediately followed by a rabbit b-globin intron and the MCS is followed
by an SV40 poly-A tail (see Fig. 1-1A for a schematic). The K14 promoter directs
expression to several tissue types, including basal cells of the skin, prostate, bladder,
forestomach, tongue, mammary myoepithelium, kidney papilla, and pancreatic ductal
epithelia.

Screening for K14-Nanog Mice
Mouse tail snips or ear punches were collected and lysed in a solution containing
25 mM NaOH and 0.2 mM EDTA at 95°C for 30 minutes, after which neutralization
buffer (40 mM Tris-HCl, pH 5) was added (HOTSHOT PROTOCOL). Five mL of this
sample was added to 20 mL polymerase chain reaction (PCR) reaction mixture
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consisting of 12.5 mL 2x GoTaq Mastermix (Promega), 5.5 mL ddH2O, and 1 mL each
of b-globin forward primer (5’-GGG-CAA-CGT-GCT-GGT-TAT-3’) and NanogP8
reverse primer (5’-CCT-TTG-GGA-CTG-GTG-GAA-3’) at 10 mM. PCR was carried
out for 35 cycles consisting of a standard melting step, an annealing temperature of 58°C
and a 45-second extension at 72°C. Products were run on a 1.5% agarose gel containing
ethidium bromide and were visualized using UV light. Transgenic mice were identified
as those bearing a ~300-bp product. Alpha Imager software (Alpha Innotech) was used
to collect images.

Epidermal Lysate
Mouse dorsal skin was shaved and Nair was applied to remove remaining hair
stubble. The hair-free skin was scraped on ice using a straight-blade razor and epidermis
was scraped until shiny dermis was evident. The epidermal scrapings were added to
lysis buffer containing 25 ul/mL protease inhibitor cocktail (Sigma) and mixed
thoroughly and the mixture was incubated for ~1 h. The lysate was centrifuged at
16,000 g for two minutes at 4°C and the supernatant was used to perform Western blot.

Harvest of Murine Organs
Mice were sacrificed using constant-flow CO2 followed by cervical dislocation.
Internal organs were removed quickly, placed directly into microcentrifuge tubes, and
were then immersed in liquid nitrogen (for Western blot). Alternatively, the organs were
placed into cassettes, which were immersed in 10% formalin for 24-48 h followed by
immersion in 70% ethanol (for immunohistochemistry). Organs were embedded in
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paraffin, sectioned, and placed on glass slides. Organ protein lysate was made by
cryopulverizing the tissue then immersing the powder in chilled lysis buffer containing
25 mL/mL protease inhibitor cocktail (Sigma). The lysate was centrifuged at 16,000 g
for two minutes at 4°C and the supernatant was used to perform Western blot.

Western Blotting Analysis
Protein samples were loaded in equal amount in each well of a 12.5%
polyacrylamide gel and electrophoresed until the protein ladder was fully resolved.
Proteins were then transferred to nitrocellulose membrane (Biorad), which was blocked
using 4% milk in TBST (Tris-buffered saline with Tween). Primary antibodies were
diluted in 4% milk/TBST and were incubated on the membrane at 4°C overnight, then
washed three times with TBST. Appropriate horseradish peroxidase-conjugated
secondary antibodies were added at a 1:2000 dilution using 4% milk/TBST as a diluent
and incubated for one hour at room temperature. The membrane was washed three times
with TBST and luminescence was produced using Western lightning ECL plus detection
reagent (Perkins Elmer).

Immunohistochemistry (IHC)
Tissues were embedded in paraffin blocks, and 4-µm sections were cut. Slides
were deparaffinized in xylene or a xylene substitute (CitraSolv; LLC, Danbury, CT) for
2 – 5 minutes. Tissues were hydrated in a series of alcohols and water before undergoing
antigen retrieval by microwaving in 10-mM citrate buffer. After antigen retrieval,
endogenous peroxidase activity was quenched with hydrogen peroxide (3% for 10
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minutes), and sections were blocked with 10% normal goat serum in phosphate-buffered
saline (PBS) for 30 minutes. Primary antibodies were applied for times ranging from 30
minutes at room temperature to overnight at 4°C. Slides were washed twice for 5
minutes each in PBS before application of the secondary antibody. For most antibodies,
slides were incubated with the secondary antibodies for 30 minutes then washed several
times with PBS. Staining was developed by incubating sections with diaminobenzidine
and tissue sections were then counterstained with hematoxylin.
To identify proliferating cells, we used an anti-Ki67 antibody; to assess
apoptosis, an anti-activated caspase-3 antibody was used; for sebocyte differentiation, an
anti-PPAR gamma antibody was employed. As an alternative method of apoptosis
detection, the Frag-EL DNA fragmentation kit from Calbiochem was used as per
manufacturer’s instructions. All counts were made on multiple sections per animal
analyzed and means were compared using Student’s t-test.

Hair Follicle Isolation and Flow Cytometry Analysis
Mice were shaved dorsally two days prior to sacrifice. Just before skin collection,
Nair was applied to remove remaining stubble. Mice were sacrificed using constant-flow
CO2 followed by cervical dislocation and then the dorsal skin was removed. Fat was
removed from the underside of the skin by thorough scraping with a curved-blade razor,
and the skin was floated dermis-side-down on 5% (w/v) dispase in DMEM overnight at
4°C. The following morning, epidermis was scraped free from the dermis, and the latter
was placed in a dish containing 1% collagenase in DMEM and incubated for ~2 h at
37°C, or until dermal disintegration was evident. Dermal remnants were then
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mechanically dispersed by pipetting and centrifuged for 5 minutes. Microscopic
inspection revealed intact hair follicles at this stage. 5 mL of 0.25% Trypsin-EDTA was
added to the hair follicle preparations for 10-15 minutes until a single-cell suspension
was obtained. These cells were then centrifuged at 1,000 rpm for 5 minutes, resuspended
in 100 mL of PBS, and incubated with appropriate fluorophore-conjugated antibodies.
Flow cytometry was performed on a BDAria cytometer and all flow cytometry data was
analyzed using the FlowJo software program. Population sizes were compared using
Student’s t-test.

Epidermal Keratinocyte Isolation and Flow Cytometry Analysis
Keratinocytes were isolated from telogen dorsal back skin using thermolysin as
described in Jensen et al (48). Briefly, the back skin strips were rinsed in 10% Betadine,
then PBS, 70% ethanol, and finally again in PBS. The dermal side was thoroughly
scraped to remove excess fat, and then the tissue was floated in 0.25 mg/ml Thermolysin
(Sigma) in calcium-free FAD medium for ~1 h at 37°C. The epidermis was then scraped
from the dermis, minced with dissecting scissors, and dispersed by gentle pipetting.
Keratinocytes were further liberated by stirring the epidermal fragments using a
magnetic stir bar. Thermolysin was inactivated by adding media containing FBS, and
the cells were washed with PBS, then pelleted and resuspended in 100 mL PBS for
labeling with antibodies to CD34, integrin a6, Lrig1, or other molecules. Flow
cytometry data was analyzed using the FlowJo software, and cell counts were compared
using Student’s t-test.
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Two-Stage Carcinogenesis Experiments
The dorsal skin of 6-8 week old mice in telogen was shaved two days prior to
application of 25 ug 7,12-Dimethylbenz(a)anthracene (DMBA) in 200-ml acetone. Two
weeks later, and for the 24-week duration of the study, dorsal skin was treated with 12.5
mg 12-O-Tetradecanoylphorbol 13-acetate (TPA) in 200-ml acetone. Papillomas were
counted weekly, and carcinomas were evaluated visually and confirmed histologically.
Mice were sacrificed prior to the study’s completion if the combined tumor burden was
excessive, if morbidity was noted, or if a single tumor exceeded acceptable size limits as
prescribed by IACUC guidelines. Both female and male FVBs were used in this study,
but were never housed together. Moreover, males were housed in small numbers in order
to minimize aggressive behavior (none was noted), which could confound tumor data. At
the study’s conclusion, tumors were harvested, counted, weighed, photographed, and
histologically analyzed. Tumor multiplicities were compared using the Mann-Whitney
non-parametric rank sum test, while comparisons between tumor incidence were made
using the Χ2 test. Tumor masses were compared using Student’s t-test.

Quantitative RT-PCR Analysis
RNA was extracted using the RNeasy mini kit (Qiagen) with on-column DNase
treatment to eradicate contaminating genomic DNA or total RNA was extracted using
the miRVana PARIS kit (Ambion), and sample quality was verified using the Agilent
Bioanalyzer. Reverse transcription was carried out using the SuperScript III First-Strand
Synthesis System (Invitrogen). Real-time primers were designed using NCBI’s Primer
Blast online software (http://www.ncbi.nlm.nih.gov/tools/primer-blast/), and genes to be
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analyzed were chosen by culling the literature for ChIP studies in which Nanog binding
was assayed. Genes to which Nanog bound near the promoter region in both mouse and
human systems were given preference as likely targets of human Nanog protein binding
to regions of the mouse genome.

In Vivo Wound Healing Experiments
Epidermal abrasion experiments were performed by shaving mice 2 days prior to
wounding. Hair stubble was removed by application of Nair just prior to epidermal
abrasion. Mice were anesthetized by inhalation of isofluorane. A felt cylinder was
attached to an electric handheld rotary tool, and wounds were made superficially such
that the dermis was just visible. Removal of epidermis and integrity of hair follicles were
both confirmed histologically on random samples.

In Vitro Wound healing (scrape) assays
Newborn keratinocyte preparations were made by washing P1-P3 pups
sequentially in Betadine, alcohol, and water, then sacrificing them using hypothermia.
Sacrificed pups were skinned and the tissue floated on 0.25% trypsin without EDTA
overnight at 4 degrees C, following which time the epidermis was gently scraped away
from the dermis, then minced with dissecting scissors. Additional keratinocytes were
dislodged from the epidermal fragments by placing the minced epidermis in a mediumcontaining dish with a magnetic stir bar and stirring for ~10 min. Keratinocytes were
isolated by filtration through a 70-mM cell strainer or by centrifugation in a Percoll
gradient.
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The migratory properties of keratinocytes were analyzed using a scrape/wound
protocol. Briefly, freshly prepared keratinocytes were plated on collagen-coated dishes
in a high-calcium Waymouth’s-based (or KBM-Gold) medium and allowed to attach for
4 h. Then the medium was changed to calcium-free KBM Gold supplemented with
.05mM calcium carbonate. Cells were allowed to reach confluence and then a pipet tip
was used to displace a line of cells along the dish’s diameter. Measurements were made
0 and 12 h post-scrape/wound, and images were collected at these time points also. The
number of cells that entered the scrape area were counted in each of multiple 40x fields,
and the means of the transgenic and wild-type groups were compared using Student’s ttest.

Label-Retaining Cell Experiments
Mouse pups were injected intraperitoneally with bromodeoxyuridine (BrdU)
twice daily from postnatal day 10 (P10) through postnatal day 12 (P12). Following a
chase period of eight weeks, the mice were sacrificed and skin was formalin-fixed and
paraffin-embedded for histological analysis and anti-BrdU immunohistochemistry.
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Chapter 3- Generation and Characterization of K14. Nanog Transgenic Mice
This project began with the intent of answering a simple question, “Does Nanog
play a role in tumor development?” Our studies using various loss-of-function
techniques in prostate cancer cell lines suggested that Nanog was a mediator of tumor
development. To address these questions in a gain-of-function setting, we first utilized
the bovine keratin 5 (BK5) promoter to generate a construct bearing HPCa5T Nanog
(NanogP8) cDNA, which was cloned from a primary prostate tumor. Implantation of
microinjected embryos bearing this DNA into pseudopregnant females yielded no
transgenic founders over the course of over six months and multiple rounds of injection
(Table 3-1). Although the keratin 5 promoter should not be active until ~E9.5,
circumstantial evidence suggested that expression of Nanog from this time point on was
sufficient to cause embryonic lethality in transgenic animals.
We then decided to utilize the human keratin 14 (K14) promoter, which is
expressed in the same cell compartment as the BK5 promoter, but is anecdotally known
to exhibit relatively reduced expression of the gene of interest. We reasoned that
perhaps we would be able to obtain transgenic founders in the absence of dramatic
overexpression of Nanog protein. Indeed, after cloning HPCa5T-Nanog cDNA
downstream of the K14 promoter (Figure 3-1A), we were successful in obtaining a
limited number of founders, four in all, over several months of embryo microinjection
and implantation of the embryos into pseudopregnant female mice. Of these potential
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Table 3-1

Table 3-1 Summary of BK5.Nanog injections
In total, 902 embryos were injected with the BK5.Nanog construct over a course of four
months (additional injections were not catalogued but were performed for two additional
months), of which 682 embryos survived (and 629 were transferred to pseudopregnant
moms). 59 pups were live-born, none of which screened positive for the transgene.
Additionally, 26 embryos and 34 “aborts” were harvested, but again no transgenics were
produced.
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founders, one did not transmit the transgene through the germline, while one mouse that
bore a wrinkled skin phenotype died two weeks postnatally. The remaining two
founders passed the transgene successfully to subsequent generations and were viable.
Line 1 is marked by relatively high Nanog expression as assessed by Western blot, while
Line 3 bears moderate transgene expression (Figure 3-2A). Characterization of the lines
generated then ensued.

Dose-dependent phenotypes in K14.Nanog mice
Phenotypically, there is a strong correlation between Nanog expression level and
severity of the observed phenotype. At the lower levels of Nanog output observed in
Line 3, there is no loss of viability and the mice appear grossly normal until about four
months of age, at which time they begin to develop cataracts that become bilateral by the
time the mouse is six months old. As an aside, Line 3 mice that do not develop cataracts
seem to express the transgene more weakly than do those Line 3 mice that possess a lens
phenotype (Figure 3-2A). Thus, it is possible that our colony at some point developed a
sub-line such that not all Line 3 mice have a propensity to develop cataracts.
Line 1 mice are characterized by perinatal lethality and possible embryonic
lethality, with an average litter size of six mice per litter (Figure 3-1C; as compared to
the standard of ~10 mice per litter when crossing wild-type FVBs) when hemizygous
males were bred to wild-type females (Homozygous transgenic mice were not generated,
i.e., hemizygous mice were not crossed due to an expected exacerbation of the reduction
in viability). This is consistent with our lack of founders when attempting to generate
transgenic mice using the BK5 promoter, and strongly suggests that overexpression of
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Nanog at prenatal time points reduces viability. Line 1 mice are much smaller than their
wild-type littermates, and this condition persists throughout birth (Figure 3-1D and E).
Additionally, Line 1 mice present with wrinkled skin at birth, and as they age they
acquire shaggy hair coats (Figure 3-1F). They also possess cataracts, and in this way
phenocopy Line 3 mice. However, Line 1 mice develop bilateral cataracts by about one
month of age, and exhibit hypopthalmia, or reduced eye size, as well. It should be noted
that this line’s gross phenotypes seem to attenuate by adulthood, though they are still
quite prominent. This effect is compounded by the early death of many transgenic mice;
those mice surviving past a critical window of roughly two weeks of age seem to bear
less striking phenotypes than those that expire earlier.
We decided to systematically analyze transgenic mice for histological
phenotypes that may not be evident to the naked eye, as the keratin 14 promoter is active
in a variety of tissues including the skin, forestomach, thymus, and tongue.

Phenotypes-skin
We began by analyzing the skin, as it exhibits the most prominent gross
phenotype in Line 1 mice. First, we confirmed proper expression of Nanog according to
the expected pattern of keratin 14 expression, and indeed Nanog was localized to basal
cells of the interfollicular epidermis as well as to the outer root sheath (ORS) of the hair
follicle (Figure 3-1H). We examined mice at P5, rationalizing that observations made in
the window prior to extensive perinatal lethality would prove fruitful. Indeed,
K14.Nanog mouse skin appears very different than that of wild-type littermates at this
time. Whereas wild-type FVB skin shows orderly follicular arrangement, a distinct
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hypodermis, and regularly interspersed sebaceous glands, K14.Nanog mice present with
disorganized follicular arrangement, a paucity of sebaceous glands, and the striking
absence of a hypodermis (Figure 3-1H).
In order to gain an appreciation for tissue homeostasis at this time point, we
conducted Ki67 staining to assess proliferation of the IFE and of hair follicles. Hair
follicles are in anagen, the proliferative phase of the hair cycle, at P5, and we confirmed
this in both transgenic and wild-type mice. We did find that transgenic mice had a
noticeable increase in proliferation of the basal cells of the IFE relative to wild-type
mice (Figure 3-1I and J), although this difference seems to abate by 2.5 weeks of age
(Figure 3-3G). This finding is augmented by the presence of keratin 6-positive cells in
both the IFE and the ORS of the hair follicle of transgenic mice, but only in the ORS of
wild-type mice (Figure 3-1K), as keratin 6 is considered to be a marker of activated or
proliferating epidermal cells (59) . As tissue homestasis is a balance between the
appearance of new cells through proliferation and the loss of existing cells, which may
occur through cell death or differentiation, we wondered at the fact that there was no
visible difference in epidermal thickness between Line 1 and wild-type mice. To
address this enigma, we performed IHC staining for suprabasal markers of IFE
differentiation including keratins 1 and 10 (Figure 3-1K). We found a slight increase in
K1/K10 in transgenic mice, which coupled with no detectable difference in apoptosis as
assessed by TUNEL staining suggests that epidermal hyperplasia was not seen as these
cells were following the normally-prescribed route of differentiation as they ascend.
However, we did note abnormal differentiation of the sebaceous gland population, one
of the three primary epidermal lineages. As mentioned previously, transgenic mice
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possess significantly fewer sebaceous glands than their wild-type littermates; this is
evident both in hemotoxylin and eosin sections and in PPAR-gamma IHC images
(Figure 3-3B and C).

Wound healing defect in K14.Nanog mice
During the course of our passive assessment for spontaneous tumor development, which
lasted upwards of 1.5 years, we noticed that adult K14.Nanog Line 1 mice developed
extensive wounding on the skin covering their ears; this occurred in the absence of
pugilism with littermates. As it was unknown whether this was behavorial in nature, i.e.,
the mice were inflicting repeated mechanical stress/damage upon themselves, or whether
these wounds were arising spontaneously as has been reported in some transgenic
models (60), we conducted formal wound healing experiments by abrading the
epidermis with a felt wheel and assessing the regrowth of the removed area. K14.Nanog
mice exhibited little re-epithelialization of the affected area, whereas wild-type mice
showed complete re-epithelialization within a week of abrasion (Figure 3-4A). It
became apparent that wounds inflicted on the transgenic mice were not healing from
inside the wound proper, but instead contraction of the bordering epithelium could be
observed. Langton and colleagues demonstrated that such auxiliary wound healing
occurs in the absence of a contribution from the hair follicle (61), which we suspected to
be the case in our wound healing system. As an aside, it appeared that transgenic mice
were more sensitive to the touch following wounding, and the exposed wounds
themselves bore a gross inflammatory character including redness along the wound
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Figure 3-1

Figure 3-1 Characterization of K14.Nanog transgenic mice
HPCa5T-derived Nanog cDNA was cloned into the human keratin 14 vector to create
the construct depicted in (A); transgenic mice were screened for using PCR as depicted
in (B). Line 1 (L1) litters are much smaller than those of Line 3 or wild-type FVBs (C).
The L1 mice themselves are smaller as well; this condition persists from birth
throughout adulthood (D and E). The most obvious adult phenotype is in the skin of L1
mice, which bear curly whiskers and shaggy hair (F). Expression of Nanog protein in
Line 1 mice is, as expected, strongest in the skin and absent in tissues lacking a keratin
14 cellular compartment (G). Analysis of the prominent skin phenotype in Line 1 mice
at P5 (H-K).
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Figure 3-2

Figure 3-2 Nanog protein expression in transgenic mice
Line 1 mice bear the strongest levels of Nanog expression in the skin as assessed by
Western blot (A) and (C). Note that Line 3 mice that harbor cataracts seem to express
more Nanog protein than transgenic mice that lack a gross phenotype. Depicted in (B) is
a systematic analysis of Nanog levels in keratin 14-expressing organs. Skin, as
expected, expressed the transgene more robustly than the other tissues. Wild-type mice
do not express mouse Nanog protein in any organs analyzed (D).
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Figure 3-3

Figure 3-3 Characterization of Line 1 skin abnormalities
K14.Nanog mice (Line 1) lack a hypodermis, have disorganized follicular placement,
and have relatively few sebocytes (A-C); the abnormalities in the skin are manifest
grossly as shown in (D). By two weeks of age, the hyperproliferative phenotype has
abated although transgenic skin is not identical to that of wild-type littermates
histologically (E-G).
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Figure 3-4

Figure 3-4 K14 Nanog mice exhibit a wound-healing defect
Epidermal abrasions heal more slowly in K14. Nanog mice than in wild-type FVBs (A).
In addition, the wounds tend to heal from without rather than from within the wound.
Markers of activated (keratin 6) and proliferating (Ki67) epidermis do not vary between
the two groups after two days’ time, although the degree of overall healing by one week
does (B). Ex vivo keratinocyte scrape assays suggest than keratinocytes derived from
transgenic mice are less capable of migrating through an artifical wound than are wildtype FVB-derived keratinocytes (C and D).
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margins. This suggests that the abrasions may cause a more pronounced inflammatory
response in transgenic mice than in wild-type controls.To better understand the observed
disparate responses to epidermal abrasion, we assessed the short-term activities of the
affected skin population histologically. In both wild-type and transgenic mice, the shortterm wound healing proliferative response as assessed by Ki67 was intact (Figure 3-4B).
Expression of keratin 6, a marker of activated epidermal cell populations that partners
with keratin 16, was identical 48 hours post-wounding as well (Figure 3-4B).
Expression of both of these keratins is essential for cells to properly migrate through the
wound area (62). H&E staining at 7 days post-wounding clearly shows that wild-type
wounds are almost fully re-epithelialized, while transgenic dorsal skin shows a
discontinuous epidermis and scabbing (Figure 3-4B).
We wondered if transgenic keratinocytes could migrate properly in response to
wounding, and to address this issue, we employed an ex vivo assay in which
keratinocytes derived from newborn pups were allowed to reach confluence, after which
time a scrape was made through the sheet of cells; this is the artifical “wound”. We
observed migration of wild-type and transgenic keratinocytes following the “wounding,”
and found that fewer transgenic keratinocytes were able to enter the wound at 12 hours
post-scrape than were wild-type cells (Figure 3-4C and D).

Phenotypes-lens
We then sought to understand the nature of the shared phenotype between Lines
1 and 3 in the ocular lens. It should be noted that the lens is not a keratin-14 expressing
cellular compartment, but several transgenic models utilizing the artificial human keratin
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14 promoter to drive expression of human papilloma viruses noted cataract formation
(63, 64); it is likely, therefore, that the human keratin 14 promoter is missing regulatory
elements such that transgene expression occurs aberrantly in the lens. In a normal lens,
epithelial cells migrate posteriorally toward the bow or ribbon region near the equator,
and as they do so they begin to enucleate and express early differentiation markers such
as p57 and later markers such as the various crystalline proteins that allow the lens its
unique optical properties.
In the K14.Nanog transgenic lens, this pattern is altered, as nucleated cells are
found posterior to the lens equator, and vacuolated cells are present within the lens as
well (Figure 3-5B and D). The presence of bladder-shaped cells in lieu of normal lens
epithelial cells suggests an altered cell fate, which we confirmed by staining for betacrystallin (Figure 3-5E). The presence of alternate cell types disrupts the normal lens
architecture such that the lens becomes opaque; it is likely also that cell-cell interactions
that serve to stabilize the overall lens architecture are abnormal as well, and that this
may be a contributing factor to the cataract phenotype. In Line 3 animals this process is
gradual and occurs over roughly six months in a Nanog dose-dependent fashion, while in
Line 1 animals cataracts are evident from as early as one month.

Phenotypes-lingual/digestive
We were interested in the digestive processes of transgenic mice, as they
appeared to feed poorly at perinatal time points, often possessing small or absent milk
spots. The stomachs of wild-type mice were quite full, but oftentimes transgenic mouse
stomachs were bereft of food, and as such had thickened adluminal epithelial layers
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(Figure 3-6A). We then analyzed the tongue for any possible abnormalities. H&E
staining shows that transgenic tongue is wrinkled and hyperkeratinized relative to that of
wild-type littermates (Figure 3-7A). Microscopic examination revealed a striking lack
of filiform papillae, the most abundant of the four types of lingual papillae that are found
on the dorsal surface and in which taste buds are located, in the tongues of P5 and twoweek-old transgenic mice (Figures 3-6B and 3-7B and C). We also noted a reduction in
the level of keratin 13, a marker of a differentiated lingual epithelium layer, and a
disruption of the normal stratified epithelial organization, again suggestive of a series of
inappropriate differentiation events (Figure 3-7E).

Phenotypes-thymus
In cataloguing the developmental abnormalities in various keratin 14-expressing organs,
we noticed a striking thymus phenotype. The thymus in K14.Nanog transgenic mice at
P5 is much smaller than that of wild-type littermates, even when these numbers are
normalized to account for differences in body mass. Even more prominent is the lack of
delineation between the medullary and cortical regions of the thymus; this lies in stark
contrast to the well-ordered boundaries between the two in wild-type thymii of agematched controls (Figure 3-6C-E). As it is known that the medulla is formed by the
expansion of progenitor cells to form islets, and that these islets coalesce to form the
structure we recognize as the medulla proper (65, 66), it is reasonable to speculate that
the apparent lack of segregation between the cortex and the medulla in transgenic mice
may in fact reflect an inability of the progenitor cell population to undergo this requisite
expansion.
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Figure 3-5

Figure 3-5 Shared lens phenotype between Line 1 and 3 transgenic mice
Cataracts are evident in both Line 1 (by 1 mo) and Line 3 mice (by 4-6 mo) (A).
Histological analysis of transgenic eyes shows nucleated cells at the posterior region of
the lens of K14. Nanog mice (B). Vacuolated cells and bladder cells are evident in tg
eyes also (B and D). B-crystallin staining shows reduced expression of this terminal
differentiation marker in tg eyes (E).
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Figure 3-6

Figure 3-6 Characterization of Digestive and Thymic Ancillary Phenotypes at P5
Transgenic mice often lack a milk spot at early perinatal time points; this finding is
confirmed by the absence of food in the stomach of tg mice, which in part leads to a
hyperkeratinization phenotype in the epithelium bordering the lumen (A). Because of
this finding, we examined the lingual epithelium of wild-type and K14. Nanog mice and
found an absence of filiform papillae (B) that is not rescued by two weeks of age. An
unrelated phenotype is found in the thymus, which in transgenic mice is
disproportionately smaller than in wild-type mice and bears a lack of distinction between
cortical and medullary regions (C,D,E).
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Figure 3-7

Figure 3-7 Abnormal differentiation in SSE of K14. Nanog tongue
K14.Nanog tongues appear grossly wrinkle and hyperkeratinized relative to those of
wild-type littermates (A). Incredibly, they also lack to a large extent the filiform
papillae, differentiated taste bud structures derive from the stratified squamous
epithelium (B and C), but retain fungiform papillae (F). Regions of hyperproliferation
corresponding to Nanog (+) cells can be observed, and staining for the differentiation
marker keratin 13 staining presents abnormally as compared to wild-type littermates (E).
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Chapter 4- Testing Nanog’s Effect on Tumor Development
Lack of tumor development in K14.Nanog mice
The thought that germinated this project is that Nanog plays a role in
tumorigenesis, but after over a year-and-a-half of passive observation, we observed no
gross tumor formation that was attributable to Nanog expression in the keratin 14
cellular compartment. This suggests that Nanog expression in keratin 14-expressing
epithelia alone is not sufficient to drive tumor formation. We therefore employed
methods known to produce tumors in hopes that we would see a perturbation of these
tumor phenotypes in K14.Nanog animals.
First, we crossed our K14.Nanog mice with K5.Myc mice in which c-Myc was
robustly expressed in the keratin 5 cellular compartment. These mice are known to
develop spontaneous tumors in the skin and mouth (67), and as such provide a platform
for us to study the role of Nanog in a setting known to foster tumor development, one in
which a known oncogene is co-expressed. We crossed both of our existing lines of
K14.Nanog mice with K5.Myc mice, but were surprised to find that we could not
recover double transgenic mice (Table 4-1); shortly thereafter we abandoned these
crosses as our data suggests that expression of both of these molecules prenatally may
result in embryonic lethality.
As an alternative to breeding schemes that would favor tumor development, we
rationalized that we could observe Nanog’s impact on several well-defined parameters of
tumor development in a two-stage skin carcinogenesis model. In this model, initiation
and promotion are separate entities that can be studied apart from one another.
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Table 4-1
K14.Nanog x K5.Myc
litter
Date of birth

1
2
3
4
5
6
7
8
9

9/25/08
9/29/08
10/7/08
10/27/08
10/30/08
11/26/08
12/30/08
1/6/09
1/12/09

Number of
pups

Line

6
3
6
3
4
4
6
4
10

1
3
3
3
1
3
1
3
3

Doublepositive
pups
expected
1.5
.75
1.5
.75
1
1
1.5
1
2.5

Doublepositive
pups
obtained
0
0
0
0
0
0
0
0
0

Table 4-1 K14.Nanog/K5.Myc breedings failed to yield double-transgenic pups
K14.Nanog mice were bred to K5.Myc mice for a period of four months with the
expectation that adult mice bearing both transgenes would develop tumors at a higher
rate and with a shorter latency than K5.Myc mice. However, double transgenic mice
were not obtained, even though a dozen mice would be expected to be liveborn were
these breedings proceeding according to Mendelian ratios.
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We began this protocol with a two-fold working hypothesis: Either 1) Nanog
expression may expand the stem/progenitor compartment (as evident in the
aforementioned Oct4-inducible transgenic model) and therefore increase the number of
potential carcinogen targets, with the outcome being a higher tumor burden or 2) Nanog
may operate more as a classical oncogene, increasing the rate of cellular proliferation (as
we observed in our P5 skin analyses) and therefore shortening tumor latency. We were
therefore puzzled when it became apparent that Line 1 K14.Nanog mice were
developing fewer tumors than their wild-type and Line 3 counterparts (Figure 4-1B and
C), and that these tumors were appearing later (at 10 weeks rather than ~8 weeks) as
well. Even more surprising was the nature of the tumors themselves: Whereas
papillomas arising in wild-type mice were fairly robust at about 40mg/tumor and
appeared partially vascularized, tumors arising in Line 1 mice were almost one-third the
size and seemed dessicated (Figure 4-1E and H). Unsurprisingly, Line 1 tumors did not,
over the course of the 24-week TPA treatment, become endophytic and progress to
SCCs, whereas wild-type and Line 3 papillomas did so at a predictable and nearly
identical rate (Figure 4-1D and F).
We explored a number of potential causes for these dramatic differences, first
dissecting the carcinogenesis protocol into its constituent steps in order to determine
where potential discrepancies may lie. First, we examined the consequences of DMBA
application by assessing apoptosis 48 hours after administration of the initiating agent.
We conducted TUNEL staining to address this issue and found no discernible difference
between wild-type and transgenic mice. As a further control, we tested Protein Kinase C
levels in both wild-type and transgenic animals, as PKC activation underlies the bulk of
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the proliferative response to TPA; we found no noticeable difference between the two
groups. We then examined the promotion step of the two-stage protocol; specifically, we
wanted to see if transgenic and wild-type epidermis proliferated in a similar fashion
when treated with repeated (every other day for two weeks) doses of TPA. Proliferation,
as assessed by Ki67 staining, was similar, and both groups exhibited the expected
epidermal thickening and hyperplasia in response to the two-week TPA regimen (Figure
4-2A and B). We therefore concluded that a short-term response to neither the initiating
nor promoting agent was impeding papilloma development.
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Figure 4-1

Figure 4-1 Two-stage skin carcinogenesis
Mice were initiated with 25ug of DMBA and, after two weeks’ time, lesions were
promoted with twice-weekly applications of TPA for a period of 24 weeks (A). Line 1
transgenic mice did not uniformly develop tumors, though Line 3 and wt mice did (B).
In addition Line 1 mice displayed a much lower tumor burden than the other groups (C,
D). The papillomas that did arise in Line 1 mice were runted and did not convert to
carcinomas (F). Histological characterization of tumors arising from all three groups
(G,H).
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Figure 4-2

Figure 4-2 Hyperplastic response to TPA treatment
Both wild-type and transgenic mice show increased Ki67 staining after two weeks of
treatment with the tumor promoter TPA (A). This is accompanied by a pronounced
hyperplasia in the IFE of FVB and K14.Nanog mice (B), suggesting a similar
proliferative response to TPA between the two groups.
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Chapter 5- Analysis of Skin Stem Cell Populations and Epidermal Gene Expression
Assessment of skin stem cell populations
We reasoned that the inhibition of skin tumor development seen in K14.Nanog
mice may be linked to the failure to repair epidermal wounds. Both processes require
the presence and participation of resident stem cell populations (54, 55, 68, 69), so we
isolated hair follicle keratinocytes and analyzed their cell surface marker profiles to look
for intact stem cell pools (depicted in Figure 1-2). We first examined the classical
CD34+, alpha6 integrin+ stem cell pool, as it is widely regarded as the most crucial and
primitive of the resident skin stem cell populations. We found that K14.Nanog skin
harbored fewer bulge stem cells than age-matched wild-type FVB mice, although the
cause of this is not immediately apparent (Figure 5-1). Strikingly, however, we noted
the apparent diminution of a CD34lowalpha6 integrinintermediate population in transgenic
animals. This population most likely lies above the region of CD34 positivity, and
therefore resides closer to the epidermis. This finding, along with our observations in P5
skin that the IFE is hyperproliferative while sebaceous glands are scarce, suggested to us
a potential loss of Lrig1+ stem cells. We therefore isolated epidermal keratinocytes
using thermolysin instead of trypsin to avoid cleavage of the relevant epitope, and
discovered that the Lrig1+ population was diminished in transgenic mice (Figure 5-1).
Since the IFE has a resident stem cell pool of slow-cycling cells, we used the labelretaining method to identify IFE LRCs by pulsing wild-type and transgenic mice with
BrdU and chasing for 6 weeks. Transgenic IFE contained only one-half the number of
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Figure 5-1

Figure 5-1 Diminution of hair follicle stem cell pools
Keratinocytes were isolated from hair follicles (for CD34, CD49f analysis) and from
epidermis (for Lrig1 analysis) of two month old wild-type and transgenic animals.
Wild-type hair follicles seem to possess a CD34lowCD49fintermediate population that is
lacking in transgenic mice (arrow-wt, hollow circle-tg).
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label-retaining cells as wild-type epidermis, although their rates of proliferation seemed
to be roughly equivalent.
Although we have observed apparent migration impediments and a diminution of
the resident stem cell pools in the skin of K14. Nanog mice, we did not have an
explanation at the level of molecular resolution. We therefore asked, “Which genes
might Nanog be affecting to bring about the observed phenotypes?” To answer this
question, we combed through published studies (14, 70-73) in which Nanog binding to
gene promoter regions was assayed. Because our transgenic model involves expression
of human Nanog in a murine system, we selected those genes whose promoters were
bound by Nanog in both mouse and human studies. These conserved targets, we
reasoned, may be preserved in our artificial system. We chose 23 genes that fit our
criteria and designed primers (which spanned introns when possible) for SYBR-greenbased qPCR analysis (Table 5-1; only specific and amplified targets presented). We
then extracted total RNA from cryopulverized mouse epidermis of each transgenic and
wild-type mice and carried out real-time PCR (results displayed in Figure 5-2).
As is often the case in Science, much of our resulting data was inconclusive, with
no clear distinction between transgenic and wild-type expression levels. In some cases,
no amplified product was observed, suggesting a lack of expression of that particular
gene in mouse skin. This group includes Sox2, a finding that is unsurprising given that
it is chiefly found in the pluripotent embryo. There were, however, a number of targets
whose altered expression may explain in part the skin phenotypes we observe; the most
prominent and exciting of this group is the mouse homolog of c-Jun, the subunit of the
AP-1 transcription factor. This protein is widely recognized as a proto-oncogene and
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has prominent roles in skin proliferation, wound healing, and inflammation. We
performed IHC staining for c-Jun and found that c-Jun seems to be expressed more
weakly in transgenic animals. Additionally, Nanog and c-Jun expression is mostly
exclusive, that is, they do not overlap to any substantial degree (Figure 5-3). One highly
relevant study demonstrated that a transactivation mutant of c-Jun, one that effectively
reduced the concentration of Ap-1 able to function transcriptionally, was able to impede
papilloma development in a two-stage protocol (DMBA/TPA) but was unable to block
TPA-induced proliferation (74). This is essentially the phenotype we see when we
subject our K14.Nanog mice to a two-stage carcinogenesis protocol.
I am unsure if this diminution of c-Jun levels is direct or indirect, however.
Although large-scale ChIP-seq studies have demonstrated that the c-Jun promoter may
be a target for Nanog binding, there exists the very small possibility that this promoter is
among those inevitable false-positive results inherent in such large-scale genome
analyses. Additionally, the binding may be authentic yet there may be no relevant
repressive activity directly exerted by Nanog. It is also possible that Nanog binding to
the promoter prevents other transcription factors from occupying certain regions
upstream of the transcription start site, and thus a direct repressive effect may exist. This
can be experimentally tested by conducting an immunoprecipitation (IP) experiment
using epidermal lysate. Immunoprecipitating Nanog will probably result in the pulldown of associated proteins, and the authenticity of these interactions can be confirmed
by performing a reciprocal IP. A final possibility, owing in no small measure to the
complexity of transcription factor gene expression networks, may be that lowered c-Jun
levels are simply an indirect consequence of Nanog expression in the skin, a locale from
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which it is normally absent, although the fact that Nanog and Jun seem not to colocalize,
i.e., Jun seems absent or low in Nanog-positive cells argues against this.
Another potentially exciting finding is that the lower levels of Bmp5 in the
epidermis of transgenic mice may explain in part our apparent stem cell depletion. A
study published in 2011 from the Morris lab showed that Bmp5 levels are strongly
correlated with and directly proportional to ex vivo colony formation and in vivo labelretaining cell number (75). Additionally, we have identified fibroblast growth factor
receptor 2 (Fgfr2) and Jmjd1a (a well-known lysine demethylase) as downregulated
genes in K14.Nanog epidermis, but have yet to follow up on the potential significance of
these finding. It is likely, of course, that our screen has failed to identify some genes
that are causally related to the skin phenotypes we have observed, and that ascribing one
gene to each observed phenotype is a dramatic oversimplification.
A close inspection of our qPCR data shows that target genes seem to be, on the
whole, repressed rather than elevated in transgenic mice (refer again to Figure 5-2). This
may reflect a direct repressive event, such as the reported binding of Nanog to Smad1,
which blocks bone morphogenic protein (BMP) signaling (76), or an indirect repressive
event, such as Nanog occupation of promoters impeding normal binding of endogenous
transcription factors.
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Table 5-1 Primers used in epidermal gene expression studies
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Figure 5-2

Figure 5-2 Epidermal gene expression panel
Genes chosen represent those whose promoters have been shown to be bound by Nanog
in human and mouse systems. Many of the genes analyzed are not significantly different
between the two groups, suggesting that Nanog may not be sufficient to regulate these
genes in the skin. However, the expression of Jun, BMP5,FGFR2, and Jmjd1a are all
drastically diminished (and statistically significant; p<.05) in transgenic skin.
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Figure 5-3

Figure 5-3 c-Jun levels are reduced in K14.Nanog epidermis
We assessed c-Jun protein levels by IHC after two weeks of treatment with the tumor
promoter TPA. K14.Nanog skin showed lower levels of the proto-oncogene than did
wild-type FVB skin (compare c to e and g). In addition, c-Jun expression is mostly
exclusive with Nanog expression (serial sections f and g), even though Nanog–
expressing cells are found basally and suprabasally in the IFE. In contrast, wild-type
skin shows more basal c-Jun expression (denoted by black arrows in c).
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Chapter 6- Ongoing Projects, Future Directions, and Significance
Ongoing-Prostate-specific Nanog expression: A constitutive model
Because much of our data concerning Nanog expression in cancer was garnered
in the prostate, we wanted to specifically and robustly express Nanog in that organ. I
cloned the HPCa5T-Nanog cDNA into the ARR2Pb vector, which directs expression
primarily to luminal cells in the dorsal, ventral, and lateral prostate lobes in the mouse
(44). We were able to easily generate founders, and characterization of F1 offspring
revealed robust Nanog expression in the expected locales. Whole-mount H&E sections
failed to reveal any hyperplastic or PIN-like lesions in mice ranging from two to six
months old (Figure 6-1), but sometimes mild luminal crowding may be seen. Although
this does not formally exclude Nanog expression from being sufficient to confer
oncogenic phenotypes in the prostate, that possibility is reinforced by our findings in the
K14.Nanog model. Additional studies to create a more favorable setting for
tumorigenesis, e.g., by increasing the activity of resident stem cells through androgendependent regression-reconstitution cycles will be undertaken in the future to address
this question. Additionally, because the probasin composite promoter is the most
common means of targeting gene expression specifically to the prostate, the possibility
exists to cross this mouse model with a transgenic mouse line bearing essentially any
oncogene of our choosing. There also exists the possibility of crossing the K14.Nanog
mouse model with the probasin-Nanog mouse to target Nanog to both the luminal and
basal cell compartments simultaneously.
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Summary/Significance
The significance of this work is multifaceted: First, we have generated two
constitutive models that allow for the study of Nanog in a number of different tissues;
similar models exist for many of the other prominent ES cell transcription factors, but
this is the first Nanog transgenic model that is available to the scientific community.
This model may be crossed with other models of various diseases, as we have done
previously, to study a potential role for Nanog in those pathological processes.
Secondly, we have demonstrated that, at least in keratin 14 cellular compartments and
possibly in prostate luminal cells, Nanog overexpression is insufficient to cause
tumorigenesis. It remains an open question as to whether or not Nanog can function
oncogenically in the context of other malignancy-predisposing events. It seems
reasonable to suspect, based on our skin tumorigenesis data, that Nanog expression at
high levels may instead confer a tumor suppressive phenotype in certain tissues. Thus,
like many proposed oncogenic molecules, Nanog expression may have varying effects
on tumor growth, progression, and the like depending on the relevant cellular context.
This dose-dependent phenotype is also very reminiscent of the role Nanog plays in ES
cells. The observed phenotypes are probably highly dependent on the transcriptional
program, or portion thereof, that Nanog can enact in somatic cells in the absence of some
if not most of the cofactors and other transcription factors with which it is normally
found in complexes in ES cells. In fibroblasts and other cells in which Nanog has been
used to induce pluripotency, neither it nor any of the other transcription factors alone can
reprogram somatic cells to a pluripotent state, and in ES cells low transcription factor
occupancy correlates with absence of gene expression.
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Future studies
There remain a number of experiments yet to be conducted involving the
K14.Nanog mouse model. The most pressing of these involves functional validation of
the stem cell depletion phenomenon seen in these mice. To address this issue, ex vivo
holoclone assays will be used as a readout of stem/progenitor cell number. If a reduction
in holoclone-forming cells is observed, then we can conclude with some confidence that
stem cell populations are diminished in K14.Nanog mice. Further, we will test whether
addition of exogenous Bmp5 can rescue this phenotype, as has been shown by the
Morris lab. If this is not the case, i.e., there is no reduction in colony-forming cells then
the altered expression of stem cell markers that we observe in our transgenic mice may
be seen instead simply as an abnormal display of cell surface markers.
Confirmation of our qPCR data is important also to solidify the conclusions we
have drawn. To this end, Western blot of epidermal lysates for c-Jun, Bmp5, and
perhaps Fgfr2 or Jmjd1a will be effected. In the case of Bmp5, this may not be feasible
as it is a secreted protein, so IHC may be used as an alternative, or, failing this, the
holoclone rescue experiments may suffice to validate our findings.
Future work beyond the scope of this mouse model will most likely entail
moving away from a constitutive model and instead using an inducible model of Nanog
expression, as any potential confounding effects owing to developmental abnormalities
will be removed by selectively expressing Nanog during adulthood. Recently, we have
overcome technical hurdles that precluded gain-of-function studies in vitro, so in order
to more accurately study Nanog in prostate cancer, the original setting in which we
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identified expression of this molecule, we will make prostate cancer cell lines the
emphasis of future work.
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Figure 6-1

Figure 6-1 Genesis and characterization of ARR2Pb- (Flag) Nanog Mice
The construct used for pronuclear injections is depicted in (A). In brief, tumor-derived
Nanog cDNA bearing an N-terminal Flag epitope is under the control of the androgenresponsive probasin promoter. (B-E) No significant differences exist in terms of gross
morphology or in histological characterization of the glandular structures in the dorsal
prostate (DP), although mild crowding of the tg lumen may be observed.
Part 2- Nanog and miR-128a
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II. Nanog and miR-128a
Chapter 7- Introduction and Background
Introduction
During our intensive work concerning Nanog’s role as a potential oncogene, the
protein remained elusive in many cell types (ex. PC3), yet our results clearly show that
reducing Nanog RNA yields a tumor-suppressive effect in these same cancer cells. This
raised the possibility that the Nanog mRNA was a biologically important species, and
further work suggested that it may be a molecular sink for one or more tumorsuppressive microRNA (miRNA) species. MicroRNAs are endogenous regulators of
gene expression; these small nucleotides are 19-22 nucleotides in their mature form and
act primarily to attenuate levels of their target mRNAs. MiRNA levels are often
perturbed in cancer; tumor-suppressive microRNAs are lost or reduced and oncogenic
miRNAs are amplified or otherwise increased. In this way, microRNAs behave
according to classic cancer gene dogma. However, whereas many oncogenes and tumor
suppressor loci have been identified, microRNAs are still something of an enigma; even
though potential tumor suppressor microRNAs and oncogenic microRNAs have been
identified, it is often unclear which mRNA targets are at the nexus of a given
microRNA’s biological effect.
We have identified a direct relationship between microRNA 128a, a tumor
suppressive microRNA with known targets that are important in prostate cancer
development, and the Nanog mRNA through its 3’ untranslated region. We are now
conducting experiments to test the biological significance of this finding.
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Background
MicroRNAs (miRNAs) are small endogenous RNA species roughly 19-22
nucleotides in length that are capable of disproportionately large feats of gene expression
modulation. Mature microRNAs act by binding to partially or fully complementary
binding sites in the 3’ untranslated region (UTR) of target messenger RNA (mRNA)
species; this binding of one or more microRNAs to their respective targets destabilizes
the message and leaves it susceptible to degradation. It has been speculated, and in some
cases demonstrated, that a single microRNA species may have hundreds of potential
targets. Conversely, each messenger RNA species may be regulated by multiple
microRNAs, depending upon the length of the 3’UTR and the number of binding sites
contained therein. Interestingly, it has also been reported that some microRNAs may act
on the coding region of target genes, e.g., (77), although the parameters that define such
interactions are less understood.
MicroRNAs were discovered quite by happenstance, and this discovery
revolutionized our way of thinking about gene expression. These small RNA species
represent a way to fine-tune messenger RNA levels, in some cases allowing for rapid
gene expression by suppressing the mRNA until removal of the relevant microRNA.
Initially, it was thought that imperfect complementarity between the microRNA seed
sequence and the 3’UTR of an mRNA resulted in transcript degradation, whereas perfect
complementarity was thought to elicit a mysterious translational repression that defied
molecular characterization. A recent study that employed high-resolution ribosome
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profiling determined that most, if not all, microRNA activity occurs through
destabilization of the transcript rather than through translational repression (78).
MicroRNAs are highly conserved and possess a myriad of functions
including developmental regulation, metabolism, and control of cellular proliferation
(79). The intervening years since the discovery of microRNAs have taught us a great
deal about their biogenesis and how this process may go awry in causing or contributing
to disease. In normal miRNA genesis, primary transcripts, known as pri-miRNA species
(which may originate from coding genes or which may be intronic in nature) are cleaved
by a Drosha-containing complex to yield pre-mRNAs. The stem-loop-bearing premiRNA is exported to the cytoplasm where it is processed by a complex that includes
Dicer along with Argonaut accessory elements . This yields the mature miRNA species
that binds in a semi-complementary fashion to a plethora of mRNA targets and effects
their destabilization, thereby rendering them unavailable for translation, or in rarer cases
involving extensive base pairing between miR and mRNA, leads to the message’s
outright destruction through RISC complex-mediated cleavage. It is well-established
that large-scale DNA alterations such as deletions, translocations, and the like can
perturb levels of pri-miRNA during neoplastic transformation, but post-transcriptional
miRNA regulation has also been postulated as a contributing factor in this process (80).
A powerful example of this is the relationship between let-7 and the RNA-binding
protein Lin28. Let-7 is considered the classical example of a tumor suppressive
microRNA, as it possesses high affinity for oncogenes such as Ras, Hmga2, and
Caspase 3 (81-83) and is diminished in lung cancer (84). Lin 28 acts to sequester let-7
and other microRNA species, which allows terminal uridyl transferases (TUTs) to
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associate with the RNA-protein complex and tag the pre-microRNA species for
degradation by adding multiple uridyl residues to the 3’end of the miRNA (85, 86).

MicroRNAs and non-coding RNA species
Recently, it has become apparent that pseudogenes may regulate microRNA
activity. Pseudogenes are molecular fossils, incomplete or otherwise non-functional,
i.e., non-protein-coding genes born of the parental locus and inserted back into the
genome in a different location (usually through a retrotransposition event). In the rare
case that such a doppleganger gene retains the ability to encode a functional protein, it is
instead designated a retrogene. Genes that are expressed embryonically are more likely
to possess pseudogenes, as transposons may be active in the relatively accessible
chromatin configuration present during this window of development. In fact, Oct-4 has
upwards of 13 pseudogenes, while Nanog has 10 pseudogenes and one retrogene. These
pseudogenes may be of two forms, processed or unprocessed, each reflecting a different
origin. Processed pseudogenes are derived from expressed mRNA that undergoes
retrotransposition and is inserted into the genome, and therefore these species lack
introns and promoters of their own. Non-processed pseudogenes arise from duplication
of the parental gene; over time and in the absence of selective pressure these duplicates
acquire mutations, deletions, and the like that render them non-functional.
Because of their similarity to transcripts encoding functional gene products,
pseudogenes are oftentimes confused for their parental transcripts, and as such
experimental design (including choice of primers) and interpretation must be undertaken
carefully. A report in 2007, issued amidst a flurry of stem cell research, cited numerous
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other studies as derelict in considering Oct-4 pseudogenes in their work, and concluded
that significant confusion had been created in the scientific community as a result (87) .
The molecular resemblance of a pseudogene to a parental gene of origin serves as
more than an experimental irritant, however. As psueudogene transcripts “look” like
bona fide protein-coding gene mRNAs, they may serve as decoys for the various
mechanisms that regulate mRNA transcripts, including microRNAs. In instances where
the transcript has retained relevant 3’UTR or coding region miRNA binding sites, the
microRNA may bind to the “artificial” transcript instead of the authentic one; in this
way, miRNA activity is diverted away from a particular gene. This phenomenon was
demonstrated convincingly using PTEN and its decoy pseudogene PTENP1 as
archetypes, as targeting of PTENP1 results in an increase in microRNA-mediated PTEN
loss (88). This ability of pseudogenes to sponge or subvert miRNA activity represents
yet another layer of regulation of microRNAs, as the mature form must navigate a sea of
potential binding partners in order to exert its influence on a “true” target.

MicroRNA 128a- a candidate tumor suppressor
Among the class of tumor suppressive microRNAs, miR-128a represents a
largely uninvestigated miR that may be highly relevant to the development and
progression of prostate cancer. It is among a handful of microRNAs that is significantly
expressed in the neuronal lineage: It is largely absent from neural stem cells (89) but is
highly expressed in mature, terminally-differentiated neurons (90). A number of recent
studies lend credence to the notion of miR-128a as a tumor suppressor in glioma,
including those that identified Bmi1 and E2F3 (91, 92), two proteins whose
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overexpression is known to contribute to tumorigenesis, as potential targets. Evidence
of mir-128a’s role in suppression of prostate cancer comes in the form of a proteomicsbased study in which miR-128a targets were found to be expressed at higher levels in
prostate adenocarcinomas than in benign prostatic tissue (93); indeed, metastatic PCa
showed even higher levels of these proteins than in situ disease, suggesting that miR128a is progressively diminished during progression of the disease. Loss of miR-128a
was shown to result in increased invasion and migration of prostate cancer cells in vitro.
Even more promising was the finding that miR-128a levels are consistently lower in
primary prostate cancer samples than in benign tissue (94). The great unknown in this
equation is how miR-128a levels are diminished in prostate cancer. To date, no
mechanism of miR-128a loss has been reported, yet all of the usual suspects are
possible, including but not limited to promoter methylation/chromatin silencing, genetic
deletion, and the tantalizing possibility that decoy mRNA transcripts are increasingly
expressed as cells become malignant.
A promising but unelaborated-upon finding in this work is the close relationship
between the Polycomb1 complex protein expression signature and that of microRNA
128a. This greatly augments the connection between miR-128a and Bmi1 in prostate
cancer and suggests an inverse relationship between the two. Bmi1 normally functions
by associating with RING1B, PH1, and CBX4 in the Polycomb1 complex; this cluster of
proteins is responsible for reading the H3K27 repressive chromatin mark laid down by
the Polycomb 2 complex, which is composed of an EZH2 enzyme, as well as EED,
SUZ12, and RBPA48 accessory proteins. Bmi1/Polycomb1 complex silencing is
thought to be dependent on the complex’s ability to add ubiquitin to H2A, which may
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result in RNA polymerase pausing or cessation of transcription (95). It is wellestablished that Bmi1 is overexpressed in many instances of prostate adenocarcinoma,
and it has been recently evinced as an important mediator of self-renewal in normal and
malignant prostatic stem-like cells (96).
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Chapter 8- Materials and Methods
Cell culture
LNCaP, PC3, and DU145 cells were cultured in RPMI media (Invitrogen)
supplemented with 8% fetal bovine serum (FBS). RWPE-1 cells were cultured in KBMGold medium (Lonza) supplemented with additional growth factors. All cell culture was
performed in antibiotic-free conditions.

Clonal and clonogenic assays
Clonal assays were conducted by plating 100 or 200 cells per well of a six-well dish
following experimental manipulation. Cells were allowed to attach for 24-48 hours
before the media was changed. Colonies were scored and photographed two weeks later.
Clonogenic assays were performed identically but cells were plated on low-attachment
tissue culture dishes. Spheres were counted and photographed two weeks post-plating.

Luciferase assays
The Nanog 3’ UTR was cloned into the MCS of pMirREPORT (Ambion); a renilla
luciferase-coding plasmid was used as an internal control. Cells were seeded 40k per
well of a 24-well dish and allowed to attach for 24 hours prior to transfection. Mir-128a
and a non-targeting control (Ambion) were transfected into target cells at a final
concentration of 32nM using either Lipofectamine 2000 or RNAiMAX (Invitrogen/Life
Technologies) reagents per the manufacturer’s protocol. 48 hours after transfection, the
Dual Luciferase assay kit (Promega) was used to induce chemiluminescence, which was
detected and measured on a Gen-Probe chemiluminometer.
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Site-directed mutagenesis
The 9-mer seed sequence of the miR-128a binding site in the Nanog 3’UTR was mutated
from 5’ TTCACTGTG to 5’ TTCGAGTTG using the Stratagene QuikChange kit as per
manufacturer’s instructions.

RNA extraction and quantification of Mir-128a
Total RNA was extracted from cultured cells using the Mirvana PARIS kit (Ambion).
Briefly, cells were lysed in a mild buffer and RNAses were inactivated with subsequent
addition of a GITC-containing buffer. Acid phenol-chloroform was added, and the
aqueous phase was harvested following centrifugation. This was mixed with 1.25x
volumes of ethanol and applied to a glass-silica column, centrifuged, washed, and eluted
with nuclease-free water. RNA integrity was analyzed on the Agilent Bioanalyzer
nanochip. MicroRNA was reverse transcribed using the Taqman MicroRNA reverse
transcription kit, and microRNA levels were determined using the Taqman Small RNA
assay assay (Applied Biosystems). Sample measurements were averaged and means
were compared using the Student’s t test.

Nanog knockdown via siRNA
Prostate cancer cells were plated and allowed to reach three-fourths confluence prior to
transfection with siNanog SMARTPOOL siRNA or non-targeting SMARTPOOL
siRNA (Dharmicon) using RNAiMAX transfection reagent (Invitrogen).

72
Nanog knockdown via lentiviral-mediated short hairpin RNA
Lentivirus bearing a short-hairpin RNA directed against Nanog or bearing no shRNA
(empty vector) was generated as previously described (36). Cells that expressed the
short hairpin or empty vector were selected by sorting for GFP+ cells using a BDAria
flow cytometer.
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Chapter 9- Examining the Nanog/miR-128a axis
Nanog regulation by mir-128a
Our previous work showed that diminution of Nanog RNA levels had a drastic impact
on prostate cancer development (36). However, our transgenic models of Nanog
overexpression, both keratin 14- and ARR2Pb-driven, failed to show any neoplastic or
even pre-neoplastic alterations. Additionally, the protein has remained elusive- as
assessed by Western blot, mass spectrometry, immunoprecipitation, etc…- in various
primary and cultured cancer cells such as PC3, although the prostate cancer cell line
DU145 numbers among those cell lines where the protein is scant yet present. A
compelling study from the Orkin lab demonstrated that the so-called “ES cell gene
expression signatures” thought to be evident in somatic cancers were in fact largely a
reflection of the transcriptional program carried out by Myc (97), a well-known
oncogene and transcription factor that is expressed at high levels in many cancer types.
We therefore could not exclude the possibility that the biologically-relevant species in a
cancerous context is the RNA rather than the protein. With the introduction of a
“ceRNA” hypothesis by the Pandolfi lab (98), one in which RNA species regulate one
another by competing for microRNA binding , we wondered if this model may apply to
our Nanog loss-of-function observations. Our animal models and subsequent in vitro
gain-of-function experiments failed to account for a potential role of the Nanog 3’UTR,
as our cloned Nanog cDNA lacks the 3’UTR that is instrumental in microRNA
regulation.
In order for Nanog to fit this paradigm, it should be capable of acting as a
molecular sink to siphon off potential tumor suppressive microRNAs from their bona
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fide targets. We therefore conducted a thorough search of the various microRNA/ miR
target databases and combined this approach with an exhaustive literature search in order
to determine if the Nanog 3’UTR contained any binding sites for tumor suppressor
microRNAs. Two independent microRNA target prediction algorithms, MicroCosm V5
and miRanda, indicate a strong binding site for mir-128a in the Nanog 3’UTR (Fig 91A). In fact, this is the only microRNA binding site in the 3’UTR that is predicted by
both computational programs.
In order to test whether or not this predicted binding could occur biologically, I
utilized the pMIR-REPORT vector into which the Nanog 3’UTR had been cloned
upstream of the firefly luciferase coding sequence. Addition of mir-128a, but not nontargeting microRNA, resulted in greatly diminished luciferase output (Fig 9-1B and C).
Mutation of the seed sequence entirely abolished miR-128a regulation of Nanog 3’UTRdependent firefly luciferase activity. This suggests that the Nanog 3’UTR is a bona fide
target of miR-128a.
To further this point, I wanted to determine if depletion of endogenous Nanog
mRNA could liberate miR-128a. I predicted that removing Nanog RNA via siRNA
knockdown would result in a net increase in the levels of miR-128a, and I therefore
transfected PC3 and LNCaP cells with siRNA (directed against Nanog or noncoding)
and assayed microRNA-128a levels 48 hours later. I found that miR-128a levels
consistently increased by about 16-17% in those cells that were robbed of Nanog mRNA
(Fig 9-2), suggesting that Nanog mRNA is a potent reservoir for miR-128a. To extend
this finding to situations in which Nanog is chronically absent, I introduced a GFPexpressing lentivirus bearing a short hairpin RNA directed against Nanog (or an empty
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vector) into PC3 cells and sorted for GFP-positive cells. Cells in which Nanog was
diminished expressed roughly 40% more miR-128a than cells that were infected with
only the empty vector.

Mir-128a as a tumor suppressor in PCa
Next, I opted to test whether miR-128a, which has been reported to inhibit
growth of glioma cells, can function as a tumor suppressor in prostate cancer cells as
well. To this end, I transfected miR-128a or non-targeting microRNA control into
LNCaP cells and assayed for clonal growth. After two weeks, only one-third the number
of cells transfected with mir-128a as compared to those transfected with a non-targeting
species had established holoclones (Fig 9-3A). Primary clonogenic assays, which
measure both a cell’s ability to grow in anchorage-independent conditions and its
proliferative capacity, revealed no difference between the two groups. However,
secondary clonogenic assays, a better representation of the stem cell-like property of
self-renewal, showed that fewer mir-128a-transfected cells could form spheres than
could non-coding miRNA-transfected cells (Fig 9-3B and C).
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Figure 9-1

Figure 9-1 Mir-128a can regulate the Nanog 3’UTR The nucleotide alignment of mir128a’s mature form and the relevant predicted binding site in the Nanog 3’UTR suggest
a strong interaction (A). Luciferase experiments confirm the strength of the interaction,
as the presence of this binding site alone is sufficient to confer a 60 percent reduction in
luciferase output when exogenous miR-128a is added (B); this phenomenon can be
observed in DU145 cells as well (C). Mutation of four nucleotides in the seed region
renders miR-128a unable to act on the Nanog 3’UTR (B); interestingly, firefly luciferase
activity soars well past the baseline.
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Figure 9-2

Figure 9-2 Reduction of endogenous Nanog levels leads to an increase in miR-128a
levels
I employed two different strategies to determine if loss of one potential target mRNA
species would result in an increase in mature, “free’ miR-128a. First, I employed a longterm, stable knockdown of Nanog by infecting PC3 cells with a lentivirus that expresses
a short hairpin RNA targeting Nanog. When compared to an empty vector control, cells
in which Nanog has been targeted show a 40-percent increase in miR-128a levels.
The second strategy uses siRNA for short-term analyses: Cancer cell lines (including
PC3 and LNCaP) in which Nanog levels have been diminished show an approximate 17
percent rise in miR-128a 48 hours after transfection with siRNA.
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Figure 9-3

Figure 9-3 Mir-128a impacts PCa cell line clonal and clonogenic growth
LNCaP cells transfected with miR-128a display one-third of the number of holoclones
relative to controls after two weeks (A). Primary clonogenic assays, which measure
anchorage-independent growth and proliferative potential, showed no difference
between cells transfected with miR-128a and those transfected with a non-targeting
artificial microRNA (B). However, secondary clonogenic assays confirm that sphereforming ability is progressively lost when exogenous mir-128a is added (B and C).
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Nanog mRNA miR-ly as a sponge?
It is likely though unproven that a given mRNA message may bind more than
one microRNA species at a time if the relevant binding sites are unoccupied, and that
this binding is dynamic and constantly in a state of equilibrium. If this is the case, then
it is also likely that the sum total of a particular RNA message’s impact on the
microRNA pool is determined by the number of miRNA binding sites and the affinity of
those binding sites for their respective microRNAs. It is therefore likely that Nanog’s
3’UTR does not only contribute to tumorigenesis by acting on miR-128a, but may act on
other species in parallel or even simultaneously. One promising target is mir-34a, a
tumor suppressive microRNA that our lab identified as a potent regulator of cancer stem
cells through CD44. We conducted preliminary studies into the possible connection
between mir-34a and Nanog, but although luciferase assays showed regulation of the
Nanog 3’UTR by mir-34a, the activity was weak and we therefore decided not to pursue
that avenue of research any further. However, a recent paper has confirmed this
regulation in demonstrating that mir-34a impedes reprogramming of somatic cell (99),
and thus it seems likely that the Nanog 3’UTR may be able to act as a sponge for this
important tumor suppressor as well.
Conversely, it is highly probable that Nanog mRNA is not the sole RNA decoy
for miR-128a (or miR-34a, for that matter). As this concept is in its nascency, a
systematic study of pseudogenes and other likely RNA sponges (e.g. long intergenic
noncoding or linc RNAs) that are expressed in somatic cancers has not been conducted.
It is likely also that protein-coding genes may be activated in order to siphon off
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microRNAs, provided that those genes’ protein products do not impose undue
proliferative or other competitive constraints on the cancer cell.
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Chapter 10- Significance and Future Directions
Future Studies
I am currently in the process of conducting in vivo xenograft experiments in
order to verify miR-128a’s potential as a tumor suppressor in prostate cancer. In
addition, I will attempt to determine if expressing the Nanog 3’UTR alone can enhance
tumorigenesis. As it is believed that Bmi1 is one of the most important targets for mir128a in the prostate, and perhaps the most important of its targets during development of
prostate cancer, I will conduct immunoprecipitation of Argonaut proteins and perform
real-time PCR in both Nanog-depleted and control samples. This would be the most
powerful method of showing that the Nanog transcript is shielding Bmi1 from
microRNA activity; it would also allow for the effect of other potentially shared
microRNAs to be observed.
Additionally, it will be important to test how Nanog mRNA functions as a
ceRNA in its native setting, that is, in ES or even embryonal carcinoma cells. In this
setting, the mRNA is much more abundantly expressed, and the protein is abundant as
well, so this may well represent an instance of a protein-coding mRNA species acting to
regulate other mRNA species. This would not be unsurprising given the complexity
inherent in establishing and maintaining the pluripotent state in the blastocyst and its in
vitro derivative. This system can also be employed in order to test whether miR-128a
activity can, as expected, decrease the level of the Nanog protein.
Exciting, large-scale studies aimed at identifying the range of ceRNAs which
Nanog mRNA may compete with for microRNA binding are beyond the scope of this
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lab’s expertise, but fully elucidating these competitors will allow for a better
appreciation of the biological role of Nanog mRNA in the setting of tumorigenesis.

Significance
It is important to determine in which cancers or even in which individual tumors
Nanog is expressed solely at the level of RNA, as we cannot rule out oncogenic activity
of the protein, although the latter seems mostly confined to germ cell tumors. This may
be because of the ironclad nature of the silencing that ES-cell/pluripotency genes seem
to undergo as they transition to somatic cells. In essence, any latent contribution to
tumor growth is strictly hypothetical as the parental genes are unable to undergo
reactivation. The form of Nanog that we detect in cancer cells originates from the
NanogP8 locus, which lacks a promoter of its own; expression from this region of the
genome is therefore very minimal. This may explain why the protein is essentially
undetectable in many cancer cell types, as the mRNA must overcome a variety of
obstacles including microRNA-induced instability and exosome activity before ever
encountering a ribosome. If further work determines that Nanog mRNA is the important
biological species in somatic tumors, this will ameliorate cancer research by deemphasizing work on the Nanog protein as a potential effector of tumorigenesis and
instead will highlight the appropriate miRs, including miR-128a, and their respective
authentic, protein-coding targets. A final possibility is that in circumstances where the
protein is evident, the Nanog mRNA and protein each may be oncogenic entities and that
their combined actions may collaborate to effect tumor development though different
mechanisms.
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